Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Upstream Bio reported Q2 2026 revenue of $0.8M and a net loss of $39.7M, with diluted EPS at $(0.73). The company advanced its lead asset Verekitug through Phase 2 trials for severe asthma and CRSwNP, with Phase 3 trials planned for Q1 2027. R&D spending increased to support accelerated development. Maruho holds exclusive commercialization rights in Japan.
Upstream Bio, Inc. reported second-quarter 2026 results with revenue of $0.8M and a net loss attributable to common stockholders of $39.7M, or diluted EPS of $(0.73), largely unchanged from the year-ago quarter.
Financial Highlights
- Revenue was $0.8M for 2Q 2026, down from $0.9M in 2Q 2025 (−17.5% YoY).
- Net income: Net loss attributable to common stockholders was $39.7M for 2Q 2026, essentially flat versus a $40.0M loss in 2Q 2025.
- Diluted EPS was $(0.73) for 2Q 2026 versus $(0.74) in 2Q 2025.
Business Highlights
- Clinical progress: Verekitug advanced through Phase 2 with positive top-line results in chronic rhinosinusitis with nasal polyps (CRSwNP) reported September 2025 and in severe asthma reported February 2026; Phase 2 COPD enrollment is complete.
- Development timeline: The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027; Phase 2 long-term extension and COPD data are expected in H2 2027.
- R&D and operations: Upstream increased R&D headcount and program spending, tracking indication-level costs for asthma, COPD and CRSwNP to support accelerated trials.
- Collaborations and commercial strategy: Maruho holds exclusive Japan commercialization rights and will reimburse development costs, while Upstream Bio retains global R&D rights.
Original SEC Filing: Upstream Bio, Inc. [ UPB ] - 10-Q - Aug. 11, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.